MX2021013842A - Composicion farmaceutica de un farmaco de acido debil y metodos de administracion. - Google Patents

Composicion farmaceutica de un farmaco de acido debil y metodos de administracion.

Info

Publication number
MX2021013842A
MX2021013842A MX2021013842A MX2021013842A MX2021013842A MX 2021013842 A MX2021013842 A MX 2021013842A MX 2021013842 A MX2021013842 A MX 2021013842A MX 2021013842 A MX2021013842 A MX 2021013842A MX 2021013842 A MX2021013842 A MX 2021013842A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
weak acid
acid drug
administration
methods
Prior art date
Application number
MX2021013842A
Other languages
English (en)
Inventor
Pei Kan
Yi Fong Lin
Ko Chieh Chen
Original Assignee
Pharmosa Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmosa Biopharm Inc filed Critical Pharmosa Biopharm Inc
Publication of MX2021013842A publication Critical patent/MX2021013842A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica que contiene liposomas, el liposoma comprende una bicapa de lípido externa; y un medio acuoso interno que incluye un fármaco de ácido débil con una vida media de menos de 2 horas. También se proporciona el uso de la composición farmacéutica descrita en la presente para tratar hipertensión pulmonar con frecuencia de dosificación reducida.
MX2021013842A 2019-05-14 2020-05-13 Composicion farmaceutica de un farmaco de acido debil y metodos de administracion. MX2021013842A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847337P 2019-05-14 2019-05-14
PCT/US2020/032563 WO2020232046A1 (en) 2019-05-14 2020-05-13 Pharmaceutical composition of a weak acid drug and methods of administration

Publications (1)

Publication Number Publication Date
MX2021013842A true MX2021013842A (es) 2022-01-18

Family

ID=73231174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013842A MX2021013842A (es) 2019-05-14 2020-05-13 Composicion farmaceutica de un farmaco de acido debil y metodos de administracion.

Country Status (13)

Country Link
US (1) US12064406B2 (es)
EP (1) EP3969002A4 (es)
JP (1) JP7445315B2 (es)
KR (1) KR20210149157A (es)
CN (1) CN113811307A (es)
AU (2) AU2020274094B2 (es)
BR (1) BR112021021875A2 (es)
CA (1) CA3139136A1 (es)
IL (1) IL287912A (es)
MX (1) MX2021013842A (es)
SG (1) SG11202112530VA (es)
TW (1) TWI757739B (es)
WO (1) WO2020232046A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024067849A1 (zh) * 2022-09-30 2024-04-04 上海济煜医药科技有限公司 一种脂质体药物组合物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
AU4981896A (en) * 1995-02-14 1996-09-04 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering liposome-loadable drugs
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
WO2003000227A2 (en) 2001-06-25 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparation of vesicles loaded with biological material and different uses thereof
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US8119156B2 (en) * 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
EP2229147A2 (en) * 2007-12-03 2010-09-22 The Johns Hopkins University Methods of synthesis and use of chemospheres
BRPI1008930A2 (pt) * 2009-02-18 2016-03-15 Aradigm Corp formulação moduladas pelo ph para liberação pulmonar
WO2011092708A2 (en) * 2010-02-01 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
JP5681276B2 (ja) * 2010-03-15 2015-03-04 ユナイテッド セラピューティクス コーポレイション 肺高血圧症のための治療
EP2827849A4 (en) * 2012-03-23 2015-11-18 Univ Leland Stanford Junior TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN
US9445993B2 (en) * 2012-04-16 2016-09-20 Rutgers, The State University Of New Jersey Nanotechnology approach for inhalation therapies
CA2890219A1 (en) * 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
BR112015022936A2 (pt) 2013-03-14 2017-07-18 J Schentag Jerome vesículas de colestossoma para a incorporação de moléculas em quilomícrons
WO2015138423A1 (en) 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
US20170246175A1 (en) * 2014-09-24 2017-08-31 Nanyang Technological University Sustained timolol maleate delivery from liposomes for glaucoma therapy and occular hypertension
TWI754659B (zh) 2016-08-08 2022-02-11 台灣微脂體股份有限公司 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
CN106214641A (zh) * 2016-08-22 2016-12-14 沈阳鑫泰格尔医药科技开发有限公司 一种适用于水溶性药物的脂质体及其制备方法
KR102337566B1 (ko) * 2017-07-24 2021-12-14 파모사 바이오팜 인코포레이티드 약산성 약물을 포함하는 리포솜 조성물 및 이의 용도
WO2019217271A1 (en) * 2018-05-07 2019-11-14 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of treprostinil

Also Published As

Publication number Publication date
AU2020274094A1 (en) 2021-11-11
JP7445315B2 (ja) 2024-03-07
JP2022532207A (ja) 2022-07-13
BR112021021875A2 (pt) 2021-12-28
TWI757739B (zh) 2022-03-11
EP3969002A4 (en) 2023-01-11
CN113811307A (zh) 2021-12-17
WO2020232046A1 (en) 2020-11-19
AU2023270346A1 (en) 2023-12-14
CA3139136A1 (en) 2020-11-19
IL287912A (en) 2022-01-01
US12064406B2 (en) 2024-08-20
EP3969002A1 (en) 2022-03-23
SG11202112530VA (en) 2021-12-30
AU2020274094B2 (en) 2023-08-31
KR20210149157A (ko) 2021-12-08
TW202108145A (zh) 2021-03-01
US20200360320A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
JP7366385B2 (ja) ヘルペスウイルス誘発疾患の処置のための方法および組成物
ECSP045140A (es) Formulaciones farmacéuticas derivadas del platino
AU2014205529B2 (en) Methods and compositions for treatment of demyelinating diseases
EA201490802A1 (ru) Препараты этанерцепта, стабилизированные меглюмином
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
MX2020014000A (es) Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas.
ATE341309T1 (de) Pulmonale arzneistoffverabreichung
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
EP4122451A8 (en) Small liposomes for delivery of immunogen-encoding rna
MX2019011491A (es) Formulaciones de niraparib.
HUP0300327A2 (hu) Percyquinnin, eljárás előállítására és gyógyászati alkalmazása
EA201291089A1 (ru) Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
EP0738152A1 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
WO2015020943A3 (en) Digestive enzyme composition suitable for enteral administration
CA2829755A1 (en) Treatment of proliferative disorders with a chemiluminescent agent
MX2022013865A (es) Materiales sintéticos similares a los lípidos para la administración al cerebro.
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
MX2021013842A (es) Composicion farmaceutica de un farmaco de acido debil y metodos de administracion.
WO2022197899A3 (en) Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
GB1380129A (en) Benzofuran derivatives and preparation thereof
MX2020010290A (es) Composiciones anestesicas de liberacion sostenida y metodos de preparacion de las mismas.
EP4014987A3 (en) Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
US20210330659A1 (en) Use of nicotinamide composition in preparation of drug for treating hand-foot skin reaction induced by sorafenib
AU2008253776A8 (en) Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence